Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05610852 · ClinicalTrials.gov registry record · NA

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

A NA study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
NA
Development phase
276
Enrollment target
1
Study location

NCT05610852: Recruiting NA study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Case Comprehensive Cancer Center.

NCT05610852 is a NA study of Prostate Cancer and Prostate Adenocarcinoma that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 276 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05610852, a NA study of Prostate Cancer and Prostate Adenocarcinoma, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
NA
Development phase
276 participants
Enrollment target
1
Study location

Study Summary

This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.

Primary Outcome

Number of patients with absence of clinically significant prostate cancer on prostate MRI and targeted prostate biopsy

Interventions

  • PROCEDURE Transvesical Single Port Robotic Partial Prostatectomy
  • PROCEDURE High-intensity focused ultrasound (HIFU)

Study Locations (1)

Ohio

  • Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 276 participants
Start Date 2024-01-01
Est. Completion 2028-07-01
Phase NA
Case Comprehensive Cancer Center

407 total trials

What NCT05610852 shows while recruiting

NCT05610852 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (55% lower).

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Transvesical Single Port Robotic Partial Prostatectomy is the first listed.

NCT05610852 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05610852 about?

NCT05610852 is a clinical study titled "Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound". This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and ...

What is the current status of trial NCT05610852?

This trial is currently recruiting. It is a NA study. The enrollment target is 276 participants. The study started on 2024-01-01. Estimated completion is 2028-07-01.

What conditions does trial NCT05610852 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma.

What interventions are being tested in trial NCT05610852?

The interventions under investigation include: Transvesical Single Port Robotic Partial Prostatectomy (PROCEDURE), High-intensity focused ultrasound (HIFU) (PROCEDURE).

Who is sponsoring clinical trial NCT05610852?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05610852 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05610852's enrollment target sits among peer trials

276 176th of 735 higher than 560 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01371630 · 276 participants · Phase 1

    Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

  • NCT04192344 · 276 participants · Phase 1

    A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

  • NCT05294991 · 276 participants · NA

    Wellness App for Sleep Disturbance in Hematological Cancer Patients

  • NCT05611931 · 276 participants · Phase 3

    Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05610852, the US trial registry maintained by the National Library of Medicine. NCT05610852 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.